Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan.

Yu Nishida,Koichi Taira,Masaki Ominami,Koji Otani,Rieko Nakata,Shuhei Hosomi,Shusei Fukunaga,Yasuaki Nagami,Noriko Kamata,Yuji Nadatani,Yasuhiro Fujiwara,Yumie Kobayashi,Fumio Tanaka

doi:10.3390/healthcare10010006

Yu Nishida, Koichi Taira + Show 11 more

Open Access

https://doi.org/10.3390/healthcare10010006

Copy DOI

Journal: Healthcare (Basel, Switzerland)	Publication Date: Dec 22, 2021
Citations: 8	License type: CC BY 4.0

Affiliation: Osaka City University

Abstract

Coronavirus disease 2019 (COVID-19) vaccination is recommended for patients with inflammatory bowel disease (IBD). However, the acceptance of COVID-19 vaccines has not been sufficiently evaluated in patients with IBD. We aimed to assess the acceptance and hesitancy of COVID-19 vaccination and related factors among these patients. A retrospective cohort study using a self-reported questionnaire was performed among patients with IBD between 22 June 2021 and 30 August 2021. Of the 187 participants, 10.2% (n = 19) were hesitant to be vaccinated. Patients in the vaccine-hesitant group were younger (p = 0.009) and had a shorter disease duration (p = 0.020). Vedolizumab was prescribed more frequently (p = 0.024) and immunomodulators were less frequently used (p = 0.027) in this group. Multivariable logistic regression analysis identified age (odds ratio [OR]: 0.96, 95% confidence interval [CI]: 0.92–1.00, p = 0.042) and the use of immunomodulators (OR: 0.08, 95% CI: 0.01–0.66, p = 0.019) as independent significant factors for vaccine hesitancy. The COVID-19 vaccine hesitancy rate in patients with IBD in Japan was 10% in this study. The Japanese COVID-19 vaccination campaign appears to be successful. The risk of COVID-19 among patients with IBD requires adequate measures to ensure that vaccines are accepted by vaccine-hesitant patients. These findings may be helpful in achieving adequate vaccination rates.

Highlights

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in December 2019 and the outbreak rapidly spread worldwide [1]
At the time of this survey, three vaccines against COVID-19 have been approved in Japan: mRNA-1273 (Moderna, Cambridge, MA, USA), BNT162b2 (Pfizer/BioNTech, New York, NY, USA), and AZD1222 (AstraZeneca, Cambridge, UK)
We found that 10.2% of patients with inflammatory bowel disease (IBD) were hesitant to get vaccinated against COVID-19, and the significantly associated factors in the adjusted analysis were the use of immunomodulators and younger age

Summary

Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in December 2019 and the outbreak rapidly spread worldwide [1]. Vaccines are authorized and recommended to prevent. The presence of a vaccine is a key element to prevent COVID-19, and to minimize new infections. It is crucial to vaccinate people to prevent the spread of COVID-19 [3]. In Japan, the COVID-19 vaccination campaign for older individuals started in April 2021, followed by people with underlying diseases, and the rest of the general population. At the time of this survey, three vaccines against COVID-19 have been approved in Japan: mRNA-1273 (Moderna, Cambridge, MA, USA), BNT162b2 (Pfizer/BioNTech, New York, NY, USA), and AZD1222

Objectives

Methods

Discussion

Conclusion